Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

• DOI: 10.1016/j.lungcan.2023.107444
• Publication Date: 2023-12-15T19:58:18Z
• Authors: Francesco Passiglia; Maria Lucia Reale; Giuseppe Lo Russo; Giulia Pasello; Gabriele Minuti; Alessandra Bulotta; Domenico Galetta; Giacomo Pelizzari; Claudio Sini; Emilio Bria; Elisa Roca; Sara Pilotto; Carlo Genova; Giulio Metro; Fabrizio Citarella; Rita Chiari; Diego Cortinovis; Angelo Delmonte; Alessandro Russo; Marcello Tiseo; Giulio Cerea; Annamaria Carta; Vieri Scotti; Tiziana Vavalà; Marta Brambilla; Lucio Buffoni; Roberta Buosi; Chiara Catania; Stefania Gori; Salvatore Grisanti; Francesco Agustoni; Edoardo Garbo; Umberto Malapelle; Silvia Novello
• Keywords: Tolerability; Discontinuation; Expanded access; Real world data; Progression-free survival

Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality life over docetaxel in patients with KRASp.G12C-mutated advanced non-small-cell lung cancer (NSCLC) within the CodeBreak-200 study. Here we report real-world efficacy tolerability data from NSCLC who received sotorasib Italian expanded access program (EAP).